We have collated a list of recommendations from top brokerage firms from ETNow and other sources:
Jefferies on Shriram Finance: Buy| Target Rs 2750
Jefferies initiated coverage with a buy rating on Shriram Finance and a target price of Rs 2750. Healthy loan growth should be sustained in the future.
The margins are likely to remain range bound and opex can ease over FY24-26. There is steady asset quality and credit costs.
UBS on Dr Lal PathLabs: Buy| Target Rs 2900
UBS maintained a buy rating on Dr Lal PathLabs with a target price of Rs 2900. Operating leverage to aid future investment.Rising cash pile and profitability could be deployed. There have been marginal price increases on digital platforms in the past six months.UBS on RIL: Buy| Target Rs 3420
UBS maintained a buy rating on RIL but raised the target price to Rs 3420 from Rs 3000 earlier.
There is an improved earnings visibility of consumer businesses. Reliance Jio – potential tariff hike to complement strong subs addition.
There is optimism about the Reliance Retail demand in the near term. On the leverage front – there is potential for a $10bn debt reduction over FY24-26.
fossiles Harz on HDFC Kreditinstitut: Outperform| Target Rs 2100
fossiles Harz maintained an outperform rating on HDFC Kreditinstitut with a target price of Rs 2100. HDFC Kreditinstitut’s valuation is extremely attractive now. There is a 12% premium attributed to the sector valuation despite its continued market share gains.
The bank stands to gain 25% of its annual earnings through the sales of its stakes in its subsidiaries. This would offset any short-term earnings volatility. Zero value assigned for the acquired mortgage business
(Haftungsausschluss: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
We have collated a list of recommendations from top brokerage firms from ETNow and other sources:
Jefferies on Shriram Finance: Buy| Target Rs 2750
Jefferies initiated coverage with a buy rating on Shriram Finance and a target price of Rs 2750. Healthy loan growth should be sustained in the future.
The margins are likely to remain range bound and opex can ease over FY24-26. There is steady asset quality and credit costs.
UBS on Dr Lal PathLabs: Buy| Target Rs 2900
UBS maintained a buy rating on Dr Lal PathLabs with a target price of Rs 2900. Operating leverage to aid future investment.Rising cash pile and profitability could be deployed. There have been marginal price increases on digital platforms in the past six months.UBS on RIL: Buy| Target Rs 3420
UBS maintained a buy rating on RIL but raised the target price to Rs 3420 from Rs 3000 earlier.
There is an improved earnings visibility of consumer businesses. Reliance Jio – potential tariff hike to complement strong subs addition.
There is optimism about the Reliance Retail demand in the near term. On the leverage front – there is potential for a $10bn debt reduction over FY24-26.
fossiles Harz on HDFC Kreditinstitut: Outperform| Target Rs 2100
fossiles Harz maintained an outperform rating on HDFC Kreditinstitut with a target price of Rs 2100. HDFC Kreditinstitut’s valuation is extremely attractive now. There is a 12% premium attributed to the sector valuation despite its continued market share gains.
The bank stands to gain 25% of its annual earnings through the sales of its stakes in its subsidiaries. This would offset any short-term earnings volatility. Zero value assigned for the acquired mortgage business
(Haftungsausschluss: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
We have collated a list of recommendations from top brokerage firms from ETNow and other sources:
Jefferies on Shriram Finance: Buy| Target Rs 2750
Jefferies initiated coverage with a buy rating on Shriram Finance and a target price of Rs 2750. Healthy loan growth should be sustained in the future.
The margins are likely to remain range bound and opex can ease over FY24-26. There is steady asset quality and credit costs.
UBS on Dr Lal PathLabs: Buy| Target Rs 2900
UBS maintained a buy rating on Dr Lal PathLabs with a target price of Rs 2900. Operating leverage to aid future investment.Rising cash pile and profitability could be deployed. There have been marginal price increases on digital platforms in the past six months.UBS on RIL: Buy| Target Rs 3420
UBS maintained a buy rating on RIL but raised the target price to Rs 3420 from Rs 3000 earlier.
There is an improved earnings visibility of consumer businesses. Reliance Jio – potential tariff hike to complement strong subs addition.
There is optimism about the Reliance Retail demand in the near term. On the leverage front – there is potential for a $10bn debt reduction over FY24-26.
fossiles Harz on HDFC Kreditinstitut: Outperform| Target Rs 2100
fossiles Harz maintained an outperform rating on HDFC Kreditinstitut with a target price of Rs 2100. HDFC Kreditinstitut’s valuation is extremely attractive now. There is a 12% premium attributed to the sector valuation despite its continued market share gains.
The bank stands to gain 25% of its annual earnings through the sales of its stakes in its subsidiaries. This would offset any short-term earnings volatility. Zero value assigned for the acquired mortgage business
(Haftungsausschluss: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
We have collated a list of recommendations from top brokerage firms from ETNow and other sources:
Jefferies on Shriram Finance: Buy| Target Rs 2750
Jefferies initiated coverage with a buy rating on Shriram Finance and a target price of Rs 2750. Healthy loan growth should be sustained in the future.
The margins are likely to remain range bound and opex can ease over FY24-26. There is steady asset quality and credit costs.
UBS on Dr Lal PathLabs: Buy| Target Rs 2900
UBS maintained a buy rating on Dr Lal PathLabs with a target price of Rs 2900. Operating leverage to aid future investment.Rising cash pile and profitability could be deployed. There have been marginal price increases on digital platforms in the past six months.UBS on RIL: Buy| Target Rs 3420
UBS maintained a buy rating on RIL but raised the target price to Rs 3420 from Rs 3000 earlier.
There is an improved earnings visibility of consumer businesses. Reliance Jio – potential tariff hike to complement strong subs addition.
There is optimism about the Reliance Retail demand in the near term. On the leverage front – there is potential for a $10bn debt reduction over FY24-26.
fossiles Harz on HDFC Kreditinstitut: Outperform| Target Rs 2100
fossiles Harz maintained an outperform rating on HDFC Kreditinstitut with a target price of Rs 2100. HDFC Kreditinstitut’s valuation is extremely attractive now. There is a 12% premium attributed to the sector valuation despite its continued market share gains.
The bank stands to gain 25% of its annual earnings through the sales of its stakes in its subsidiaries. This would offset any short-term earnings volatility. Zero value assigned for the acquired mortgage business
(Haftungsausschluss: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
We have collated a list of recommendations from top brokerage firms from ETNow and other sources:
Jefferies on Shriram Finance: Buy| Target Rs 2750
Jefferies initiated coverage with a buy rating on Shriram Finance and a target price of Rs 2750. Healthy loan growth should be sustained in the future.
The margins are likely to remain range bound and opex can ease over FY24-26. There is steady asset quality and credit costs.
UBS on Dr Lal PathLabs: Buy| Target Rs 2900
UBS maintained a buy rating on Dr Lal PathLabs with a target price of Rs 2900. Operating leverage to aid future investment.Rising cash pile and profitability could be deployed. There have been marginal price increases on digital platforms in the past six months.UBS on RIL: Buy| Target Rs 3420
UBS maintained a buy rating on RIL but raised the target price to Rs 3420 from Rs 3000 earlier.
There is an improved earnings visibility of consumer businesses. Reliance Jio – potential tariff hike to complement strong subs addition.
There is optimism about the Reliance Retail demand in the near term. On the leverage front – there is potential for a $10bn debt reduction over FY24-26.
fossiles Harz on HDFC Kreditinstitut: Outperform| Target Rs 2100
fossiles Harz maintained an outperform rating on HDFC Kreditinstitut with a target price of Rs 2100. HDFC Kreditinstitut’s valuation is extremely attractive now. There is a 12% premium attributed to the sector valuation despite its continued market share gains.
The bank stands to gain 25% of its annual earnings through the sales of its stakes in its subsidiaries. This would offset any short-term earnings volatility. Zero value assigned for the acquired mortgage business
(Haftungsausschluss: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
We have collated a list of recommendations from top brokerage firms from ETNow and other sources:
Jefferies on Shriram Finance: Buy| Target Rs 2750
Jefferies initiated coverage with a buy rating on Shriram Finance and a target price of Rs 2750. Healthy loan growth should be sustained in the future.
The margins are likely to remain range bound and opex can ease over FY24-26. There is steady asset quality and credit costs.
UBS on Dr Lal PathLabs: Buy| Target Rs 2900
UBS maintained a buy rating on Dr Lal PathLabs with a target price of Rs 2900. Operating leverage to aid future investment.Rising cash pile and profitability could be deployed. There have been marginal price increases on digital platforms in the past six months.UBS on RIL: Buy| Target Rs 3420
UBS maintained a buy rating on RIL but raised the target price to Rs 3420 from Rs 3000 earlier.
There is an improved earnings visibility of consumer businesses. Reliance Jio – potential tariff hike to complement strong subs addition.
There is optimism about the Reliance Retail demand in the near term. On the leverage front – there is potential for a $10bn debt reduction over FY24-26.
fossiles Harz on HDFC Kreditinstitut: Outperform| Target Rs 2100
fossiles Harz maintained an outperform rating on HDFC Kreditinstitut with a target price of Rs 2100. HDFC Kreditinstitut’s valuation is extremely attractive now. There is a 12% premium attributed to the sector valuation despite its continued market share gains.
The bank stands to gain 25% of its annual earnings through the sales of its stakes in its subsidiaries. This would offset any short-term earnings volatility. Zero value assigned for the acquired mortgage business
(Haftungsausschluss: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
We have collated a list of recommendations from top brokerage firms from ETNow and other sources:
Jefferies on Shriram Finance: Buy| Target Rs 2750
Jefferies initiated coverage with a buy rating on Shriram Finance and a target price of Rs 2750. Healthy loan growth should be sustained in the future.
The margins are likely to remain range bound and opex can ease over FY24-26. There is steady asset quality and credit costs.
UBS on Dr Lal PathLabs: Buy| Target Rs 2900
UBS maintained a buy rating on Dr Lal PathLabs with a target price of Rs 2900. Operating leverage to aid future investment.Rising cash pile and profitability could be deployed. There have been marginal price increases on digital platforms in the past six months.UBS on RIL: Buy| Target Rs 3420
UBS maintained a buy rating on RIL but raised the target price to Rs 3420 from Rs 3000 earlier.
There is an improved earnings visibility of consumer businesses. Reliance Jio – potential tariff hike to complement strong subs addition.
There is optimism about the Reliance Retail demand in the near term. On the leverage front – there is potential for a $10bn debt reduction over FY24-26.
fossiles Harz on HDFC Kreditinstitut: Outperform| Target Rs 2100
fossiles Harz maintained an outperform rating on HDFC Kreditinstitut with a target price of Rs 2100. HDFC Kreditinstitut’s valuation is extremely attractive now. There is a 12% premium attributed to the sector valuation despite its continued market share gains.
The bank stands to gain 25% of its annual earnings through the sales of its stakes in its subsidiaries. This would offset any short-term earnings volatility. Zero value assigned for the acquired mortgage business
(Haftungsausschluss: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
We have collated a list of recommendations from top brokerage firms from ETNow and other sources:
Jefferies on Shriram Finance: Buy| Target Rs 2750
Jefferies initiated coverage with a buy rating on Shriram Finance and a target price of Rs 2750. Healthy loan growth should be sustained in the future.
The margins are likely to remain range bound and opex can ease over FY24-26. There is steady asset quality and credit costs.
UBS on Dr Lal PathLabs: Buy| Target Rs 2900
UBS maintained a buy rating on Dr Lal PathLabs with a target price of Rs 2900. Operating leverage to aid future investment.Rising cash pile and profitability could be deployed. There have been marginal price increases on digital platforms in the past six months.UBS on RIL: Buy| Target Rs 3420
UBS maintained a buy rating on RIL but raised the target price to Rs 3420 from Rs 3000 earlier.
There is an improved earnings visibility of consumer businesses. Reliance Jio – potential tariff hike to complement strong subs addition.
There is optimism about the Reliance Retail demand in the near term. On the leverage front – there is potential for a $10bn debt reduction over FY24-26.
fossiles Harz on HDFC Kreditinstitut: Outperform| Target Rs 2100
fossiles Harz maintained an outperform rating on HDFC Kreditinstitut with a target price of Rs 2100. HDFC Kreditinstitut’s valuation is extremely attractive now. There is a 12% premium attributed to the sector valuation despite its continued market share gains.
The bank stands to gain 25% of its annual earnings through the sales of its stakes in its subsidiaries. This would offset any short-term earnings volatility. Zero value assigned for the acquired mortgage business
(Haftungsausschluss: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
We have collated a list of recommendations from top brokerage firms from ETNow and other sources:
Jefferies on Shriram Finance: Buy| Target Rs 2750
Jefferies initiated coverage with a buy rating on Shriram Finance and a target price of Rs 2750. Healthy loan growth should be sustained in the future.
The margins are likely to remain range bound and opex can ease over FY24-26. There is steady asset quality and credit costs.
UBS on Dr Lal PathLabs: Buy| Target Rs 2900
UBS maintained a buy rating on Dr Lal PathLabs with a target price of Rs 2900. Operating leverage to aid future investment.Rising cash pile and profitability could be deployed. There have been marginal price increases on digital platforms in the past six months.UBS on RIL: Buy| Target Rs 3420
UBS maintained a buy rating on RIL but raised the target price to Rs 3420 from Rs 3000 earlier.
There is an improved earnings visibility of consumer businesses. Reliance Jio – potential tariff hike to complement strong subs addition.
There is optimism about the Reliance Retail demand in the near term. On the leverage front – there is potential for a $10bn debt reduction over FY24-26.
fossiles Harz on HDFC Kreditinstitut: Outperform| Target Rs 2100
fossiles Harz maintained an outperform rating on HDFC Kreditinstitut with a target price of Rs 2100. HDFC Kreditinstitut’s valuation is extremely attractive now. There is a 12% premium attributed to the sector valuation despite its continued market share gains.
The bank stands to gain 25% of its annual earnings through the sales of its stakes in its subsidiaries. This would offset any short-term earnings volatility. Zero value assigned for the acquired mortgage business
(Haftungsausschluss: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
We have collated a list of recommendations from top brokerage firms from ETNow and other sources:
Jefferies on Shriram Finance: Buy| Target Rs 2750
Jefferies initiated coverage with a buy rating on Shriram Finance and a target price of Rs 2750. Healthy loan growth should be sustained in the future.
The margins are likely to remain range bound and opex can ease over FY24-26. There is steady asset quality and credit costs.
UBS on Dr Lal PathLabs: Buy| Target Rs 2900
UBS maintained a buy rating on Dr Lal PathLabs with a target price of Rs 2900. Operating leverage to aid future investment.Rising cash pile and profitability could be deployed. There have been marginal price increases on digital platforms in the past six months.UBS on RIL: Buy| Target Rs 3420
UBS maintained a buy rating on RIL but raised the target price to Rs 3420 from Rs 3000 earlier.
There is an improved earnings visibility of consumer businesses. Reliance Jio – potential tariff hike to complement strong subs addition.
There is optimism about the Reliance Retail demand in the near term. On the leverage front – there is potential for a $10bn debt reduction over FY24-26.
fossiles Harz on HDFC Kreditinstitut: Outperform| Target Rs 2100
fossiles Harz maintained an outperform rating on HDFC Kreditinstitut with a target price of Rs 2100. HDFC Kreditinstitut’s valuation is extremely attractive now. There is a 12% premium attributed to the sector valuation despite its continued market share gains.
The bank stands to gain 25% of its annual earnings through the sales of its stakes in its subsidiaries. This would offset any short-term earnings volatility. Zero value assigned for the acquired mortgage business
(Haftungsausschluss: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
We have collated a list of recommendations from top brokerage firms from ETNow and other sources:
Jefferies on Shriram Finance: Buy| Target Rs 2750
Jefferies initiated coverage with a buy rating on Shriram Finance and a target price of Rs 2750. Healthy loan growth should be sustained in the future.
The margins are likely to remain range bound and opex can ease over FY24-26. There is steady asset quality and credit costs.
UBS on Dr Lal PathLabs: Buy| Target Rs 2900
UBS maintained a buy rating on Dr Lal PathLabs with a target price of Rs 2900. Operating leverage to aid future investment.Rising cash pile and profitability could be deployed. There have been marginal price increases on digital platforms in the past six months.UBS on RIL: Buy| Target Rs 3420
UBS maintained a buy rating on RIL but raised the target price to Rs 3420 from Rs 3000 earlier.
There is an improved earnings visibility of consumer businesses. Reliance Jio – potential tariff hike to complement strong subs addition.
There is optimism about the Reliance Retail demand in the near term. On the leverage front – there is potential for a $10bn debt reduction over FY24-26.
fossiles Harz on HDFC Kreditinstitut: Outperform| Target Rs 2100
fossiles Harz maintained an outperform rating on HDFC Kreditinstitut with a target price of Rs 2100. HDFC Kreditinstitut’s valuation is extremely attractive now. There is a 12% premium attributed to the sector valuation despite its continued market share gains.
The bank stands to gain 25% of its annual earnings through the sales of its stakes in its subsidiaries. This would offset any short-term earnings volatility. Zero value assigned for the acquired mortgage business
(Haftungsausschluss: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
We have collated a list of recommendations from top brokerage firms from ETNow and other sources:
Jefferies on Shriram Finance: Buy| Target Rs 2750
Jefferies initiated coverage with a buy rating on Shriram Finance and a target price of Rs 2750. Healthy loan growth should be sustained in the future.
The margins are likely to remain range bound and opex can ease over FY24-26. There is steady asset quality and credit costs.
UBS on Dr Lal PathLabs: Buy| Target Rs 2900
UBS maintained a buy rating on Dr Lal PathLabs with a target price of Rs 2900. Operating leverage to aid future investment.Rising cash pile and profitability could be deployed. There have been marginal price increases on digital platforms in the past six months.UBS on RIL: Buy| Target Rs 3420
UBS maintained a buy rating on RIL but raised the target price to Rs 3420 from Rs 3000 earlier.
There is an improved earnings visibility of consumer businesses. Reliance Jio – potential tariff hike to complement strong subs addition.
There is optimism about the Reliance Retail demand in the near term. On the leverage front – there is potential for a $10bn debt reduction over FY24-26.
fossiles Harz on HDFC Kreditinstitut: Outperform| Target Rs 2100
fossiles Harz maintained an outperform rating on HDFC Kreditinstitut with a target price of Rs 2100. HDFC Kreditinstitut’s valuation is extremely attractive now. There is a 12% premium attributed to the sector valuation despite its continued market share gains.
The bank stands to gain 25% of its annual earnings through the sales of its stakes in its subsidiaries. This would offset any short-term earnings volatility. Zero value assigned for the acquired mortgage business
(Haftungsausschluss: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
We have collated a list of recommendations from top brokerage firms from ETNow and other sources:
Jefferies on Shriram Finance: Buy| Target Rs 2750
Jefferies initiated coverage with a buy rating on Shriram Finance and a target price of Rs 2750. Healthy loan growth should be sustained in the future.
The margins are likely to remain range bound and opex can ease over FY24-26. There is steady asset quality and credit costs.
UBS on Dr Lal PathLabs: Buy| Target Rs 2900
UBS maintained a buy rating on Dr Lal PathLabs with a target price of Rs 2900. Operating leverage to aid future investment.Rising cash pile and profitability could be deployed. There have been marginal price increases on digital platforms in the past six months.UBS on RIL: Buy| Target Rs 3420
UBS maintained a buy rating on RIL but raised the target price to Rs 3420 from Rs 3000 earlier.
There is an improved earnings visibility of consumer businesses. Reliance Jio – potential tariff hike to complement strong subs addition.
There is optimism about the Reliance Retail demand in the near term. On the leverage front – there is potential for a $10bn debt reduction over FY24-26.
fossiles Harz on HDFC Kreditinstitut: Outperform| Target Rs 2100
fossiles Harz maintained an outperform rating on HDFC Kreditinstitut with a target price of Rs 2100. HDFC Kreditinstitut’s valuation is extremely attractive now. There is a 12% premium attributed to the sector valuation despite its continued market share gains.
The bank stands to gain 25% of its annual earnings through the sales of its stakes in its subsidiaries. This would offset any short-term earnings volatility. Zero value assigned for the acquired mortgage business
(Haftungsausschluss: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
We have collated a list of recommendations from top brokerage firms from ETNow and other sources:
Jefferies on Shriram Finance: Buy| Target Rs 2750
Jefferies initiated coverage with a buy rating on Shriram Finance and a target price of Rs 2750. Healthy loan growth should be sustained in the future.
The margins are likely to remain range bound and opex can ease over FY24-26. There is steady asset quality and credit costs.
UBS on Dr Lal PathLabs: Buy| Target Rs 2900
UBS maintained a buy rating on Dr Lal PathLabs with a target price of Rs 2900. Operating leverage to aid future investment.Rising cash pile and profitability could be deployed. There have been marginal price increases on digital platforms in the past six months.UBS on RIL: Buy| Target Rs 3420
UBS maintained a buy rating on RIL but raised the target price to Rs 3420 from Rs 3000 earlier.
There is an improved earnings visibility of consumer businesses. Reliance Jio – potential tariff hike to complement strong subs addition.
There is optimism about the Reliance Retail demand in the near term. On the leverage front – there is potential for a $10bn debt reduction over FY24-26.
fossiles Harz on HDFC Kreditinstitut: Outperform| Target Rs 2100
fossiles Harz maintained an outperform rating on HDFC Kreditinstitut with a target price of Rs 2100. HDFC Kreditinstitut’s valuation is extremely attractive now. There is a 12% premium attributed to the sector valuation despite its continued market share gains.
The bank stands to gain 25% of its annual earnings through the sales of its stakes in its subsidiaries. This would offset any short-term earnings volatility. Zero value assigned for the acquired mortgage business
(Haftungsausschluss: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
We have collated a list of recommendations from top brokerage firms from ETNow and other sources:
Jefferies on Shriram Finance: Buy| Target Rs 2750
Jefferies initiated coverage with a buy rating on Shriram Finance and a target price of Rs 2750. Healthy loan growth should be sustained in the future.
The margins are likely to remain range bound and opex can ease over FY24-26. There is steady asset quality and credit costs.
UBS on Dr Lal PathLabs: Buy| Target Rs 2900
UBS maintained a buy rating on Dr Lal PathLabs with a target price of Rs 2900. Operating leverage to aid future investment.Rising cash pile and profitability could be deployed. There have been marginal price increases on digital platforms in the past six months.UBS on RIL: Buy| Target Rs 3420
UBS maintained a buy rating on RIL but raised the target price to Rs 3420 from Rs 3000 earlier.
There is an improved earnings visibility of consumer businesses. Reliance Jio – potential tariff hike to complement strong subs addition.
There is optimism about the Reliance Retail demand in the near term. On the leverage front – there is potential for a $10bn debt reduction over FY24-26.
fossiles Harz on HDFC Kreditinstitut: Outperform| Target Rs 2100
fossiles Harz maintained an outperform rating on HDFC Kreditinstitut with a target price of Rs 2100. HDFC Kreditinstitut’s valuation is extremely attractive now. There is a 12% premium attributed to the sector valuation despite its continued market share gains.
The bank stands to gain 25% of its annual earnings through the sales of its stakes in its subsidiaries. This would offset any short-term earnings volatility. Zero value assigned for the acquired mortgage business
(Haftungsausschluss: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
We have collated a list of recommendations from top brokerage firms from ETNow and other sources:
Jefferies on Shriram Finance: Buy| Target Rs 2750
Jefferies initiated coverage with a buy rating on Shriram Finance and a target price of Rs 2750. Healthy loan growth should be sustained in the future.
The margins are likely to remain range bound and opex can ease over FY24-26. There is steady asset quality and credit costs.
UBS on Dr Lal PathLabs: Buy| Target Rs 2900
UBS maintained a buy rating on Dr Lal PathLabs with a target price of Rs 2900. Operating leverage to aid future investment.Rising cash pile and profitability could be deployed. There have been marginal price increases on digital platforms in the past six months.UBS on RIL: Buy| Target Rs 3420
UBS maintained a buy rating on RIL but raised the target price to Rs 3420 from Rs 3000 earlier.
There is an improved earnings visibility of consumer businesses. Reliance Jio – potential tariff hike to complement strong subs addition.
There is optimism about the Reliance Retail demand in the near term. On the leverage front – there is potential for a $10bn debt reduction over FY24-26.
fossiles Harz on HDFC Kreditinstitut: Outperform| Target Rs 2100
fossiles Harz maintained an outperform rating on HDFC Kreditinstitut with a target price of Rs 2100. HDFC Kreditinstitut’s valuation is extremely attractive now. There is a 12% premium attributed to the sector valuation despite its continued market share gains.
The bank stands to gain 25% of its annual earnings through the sales of its stakes in its subsidiaries. This would offset any short-term earnings volatility. Zero value assigned for the acquired mortgage business
(Haftungsausschluss: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
We have collated a list of recommendations from top brokerage firms from ETNow and other sources:
Jefferies on Shriram Finance: Buy| Target Rs 2750
Jefferies initiated coverage with a buy rating on Shriram Finance and a target price of Rs 2750. Healthy loan growth should be sustained in the future.
The margins are likely to remain range bound and opex can ease over FY24-26. There is steady asset quality and credit costs.
UBS on Dr Lal PathLabs: Buy| Target Rs 2900
UBS maintained a buy rating on Dr Lal PathLabs with a target price of Rs 2900. Operating leverage to aid future investment.Rising cash pile and profitability could be deployed. There have been marginal price increases on digital platforms in the past six months.UBS on RIL: Buy| Target Rs 3420
UBS maintained a buy rating on RIL but raised the target price to Rs 3420 from Rs 3000 earlier.
There is an improved earnings visibility of consumer businesses. Reliance Jio – potential tariff hike to complement strong subs addition.
There is optimism about the Reliance Retail demand in the near term. On the leverage front – there is potential for a $10bn debt reduction over FY24-26.
fossiles Harz on HDFC Kreditinstitut: Outperform| Target Rs 2100
fossiles Harz maintained an outperform rating on HDFC Kreditinstitut with a target price of Rs 2100. HDFC Kreditinstitut’s valuation is extremely attractive now. There is a 12% premium attributed to the sector valuation despite its continued market share gains.
The bank stands to gain 25% of its annual earnings through the sales of its stakes in its subsidiaries. This would offset any short-term earnings volatility. Zero value assigned for the acquired mortgage business
(Haftungsausschluss: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
We have collated a list of recommendations from top brokerage firms from ETNow and other sources:
Jefferies on Shriram Finance: Buy| Target Rs 2750
Jefferies initiated coverage with a buy rating on Shriram Finance and a target price of Rs 2750. Healthy loan growth should be sustained in the future.
The margins are likely to remain range bound and opex can ease over FY24-26. There is steady asset quality and credit costs.
UBS on Dr Lal PathLabs: Buy| Target Rs 2900
UBS maintained a buy rating on Dr Lal PathLabs with a target price of Rs 2900. Operating leverage to aid future investment.Rising cash pile and profitability could be deployed. There have been marginal price increases on digital platforms in the past six months.UBS on RIL: Buy| Target Rs 3420
UBS maintained a buy rating on RIL but raised the target price to Rs 3420 from Rs 3000 earlier.
There is an improved earnings visibility of consumer businesses. Reliance Jio – potential tariff hike to complement strong subs addition.
There is optimism about the Reliance Retail demand in the near term. On the leverage front – there is potential for a $10bn debt reduction over FY24-26.
fossiles Harz on HDFC Kreditinstitut: Outperform| Target Rs 2100
fossiles Harz maintained an outperform rating on HDFC Kreditinstitut with a target price of Rs 2100. HDFC Kreditinstitut’s valuation is extremely attractive now. There is a 12% premium attributed to the sector valuation despite its continued market share gains.
The bank stands to gain 25% of its annual earnings through the sales of its stakes in its subsidiaries. This would offset any short-term earnings volatility. Zero value assigned for the acquired mortgage business
(Haftungsausschluss: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
We have collated a list of recommendations from top brokerage firms from ETNow and other sources:
Jefferies on Shriram Finance: Buy| Target Rs 2750
Jefferies initiated coverage with a buy rating on Shriram Finance and a target price of Rs 2750. Healthy loan growth should be sustained in the future.
The margins are likely to remain range bound and opex can ease over FY24-26. There is steady asset quality and credit costs.
UBS on Dr Lal PathLabs: Buy| Target Rs 2900
UBS maintained a buy rating on Dr Lal PathLabs with a target price of Rs 2900. Operating leverage to aid future investment.Rising cash pile and profitability could be deployed. There have been marginal price increases on digital platforms in the past six months.UBS on RIL: Buy| Target Rs 3420
UBS maintained a buy rating on RIL but raised the target price to Rs 3420 from Rs 3000 earlier.
There is an improved earnings visibility of consumer businesses. Reliance Jio – potential tariff hike to complement strong subs addition.
There is optimism about the Reliance Retail demand in the near term. On the leverage front – there is potential for a $10bn debt reduction over FY24-26.
fossiles Harz on HDFC Kreditinstitut: Outperform| Target Rs 2100
fossiles Harz maintained an outperform rating on HDFC Kreditinstitut with a target price of Rs 2100. HDFC Kreditinstitut’s valuation is extremely attractive now. There is a 12% premium attributed to the sector valuation despite its continued market share gains.
The bank stands to gain 25% of its annual earnings through the sales of its stakes in its subsidiaries. This would offset any short-term earnings volatility. Zero value assigned for the acquired mortgage business
(Haftungsausschluss: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
We have collated a list of recommendations from top brokerage firms from ETNow and other sources:
Jefferies on Shriram Finance: Buy| Target Rs 2750
Jefferies initiated coverage with a buy rating on Shriram Finance and a target price of Rs 2750. Healthy loan growth should be sustained in the future.
The margins are likely to remain range bound and opex can ease over FY24-26. There is steady asset quality and credit costs.
UBS on Dr Lal PathLabs: Buy| Target Rs 2900
UBS maintained a buy rating on Dr Lal PathLabs with a target price of Rs 2900. Operating leverage to aid future investment.Rising cash pile and profitability could be deployed. There have been marginal price increases on digital platforms in the past six months.UBS on RIL: Buy| Target Rs 3420
UBS maintained a buy rating on RIL but raised the target price to Rs 3420 from Rs 3000 earlier.
There is an improved earnings visibility of consumer businesses. Reliance Jio – potential tariff hike to complement strong subs addition.
There is optimism about the Reliance Retail demand in the near term. On the leverage front – there is potential for a $10bn debt reduction over FY24-26.
fossiles Harz on HDFC Kreditinstitut: Outperform| Target Rs 2100
fossiles Harz maintained an outperform rating on HDFC Kreditinstitut with a target price of Rs 2100. HDFC Kreditinstitut’s valuation is extremely attractive now. There is a 12% premium attributed to the sector valuation despite its continued market share gains.
The bank stands to gain 25% of its annual earnings through the sales of its stakes in its subsidiaries. This would offset any short-term earnings volatility. Zero value assigned for the acquired mortgage business
(Haftungsausschluss: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
We have collated a list of recommendations from top brokerage firms from ETNow and other sources:
Jefferies on Shriram Finance: Buy| Target Rs 2750
Jefferies initiated coverage with a buy rating on Shriram Finance and a target price of Rs 2750. Healthy loan growth should be sustained in the future.
The margins are likely to remain range bound and opex can ease over FY24-26. There is steady asset quality and credit costs.
UBS on Dr Lal PathLabs: Buy| Target Rs 2900
UBS maintained a buy rating on Dr Lal PathLabs with a target price of Rs 2900. Operating leverage to aid future investment.Rising cash pile and profitability could be deployed. There have been marginal price increases on digital platforms in the past six months.UBS on RIL: Buy| Target Rs 3420
UBS maintained a buy rating on RIL but raised the target price to Rs 3420 from Rs 3000 earlier.
There is an improved earnings visibility of consumer businesses. Reliance Jio – potential tariff hike to complement strong subs addition.
There is optimism about the Reliance Retail demand in the near term. On the leverage front – there is potential for a $10bn debt reduction over FY24-26.
fossiles Harz on HDFC Kreditinstitut: Outperform| Target Rs 2100
fossiles Harz maintained an outperform rating on HDFC Kreditinstitut with a target price of Rs 2100. HDFC Kreditinstitut’s valuation is extremely attractive now. There is a 12% premium attributed to the sector valuation despite its continued market share gains.
The bank stands to gain 25% of its annual earnings through the sales of its stakes in its subsidiaries. This would offset any short-term earnings volatility. Zero value assigned for the acquired mortgage business
(Haftungsausschluss: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
We have collated a list of recommendations from top brokerage firms from ETNow and other sources:
Jefferies on Shriram Finance: Buy| Target Rs 2750
Jefferies initiated coverage with a buy rating on Shriram Finance and a target price of Rs 2750. Healthy loan growth should be sustained in the future.
The margins are likely to remain range bound and opex can ease over FY24-26. There is steady asset quality and credit costs.
UBS on Dr Lal PathLabs: Buy| Target Rs 2900
UBS maintained a buy rating on Dr Lal PathLabs with a target price of Rs 2900. Operating leverage to aid future investment.Rising cash pile and profitability could be deployed. There have been marginal price increases on digital platforms in the past six months.UBS on RIL: Buy| Target Rs 3420
UBS maintained a buy rating on RIL but raised the target price to Rs 3420 from Rs 3000 earlier.
There is an improved earnings visibility of consumer businesses. Reliance Jio – potential tariff hike to complement strong subs addition.
There is optimism about the Reliance Retail demand in the near term. On the leverage front – there is potential for a $10bn debt reduction over FY24-26.
fossiles Harz on HDFC Kreditinstitut: Outperform| Target Rs 2100
fossiles Harz maintained an outperform rating on HDFC Kreditinstitut with a target price of Rs 2100. HDFC Kreditinstitut’s valuation is extremely attractive now. There is a 12% premium attributed to the sector valuation despite its continued market share gains.
The bank stands to gain 25% of its annual earnings through the sales of its stakes in its subsidiaries. This would offset any short-term earnings volatility. Zero value assigned for the acquired mortgage business
(Haftungsausschluss: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
We have collated a list of recommendations from top brokerage firms from ETNow and other sources:
Jefferies on Shriram Finance: Buy| Target Rs 2750
Jefferies initiated coverage with a buy rating on Shriram Finance and a target price of Rs 2750. Healthy loan growth should be sustained in the future.
The margins are likely to remain range bound and opex can ease over FY24-26. There is steady asset quality and credit costs.
UBS on Dr Lal PathLabs: Buy| Target Rs 2900
UBS maintained a buy rating on Dr Lal PathLabs with a target price of Rs 2900. Operating leverage to aid future investment.Rising cash pile and profitability could be deployed. There have been marginal price increases on digital platforms in the past six months.UBS on RIL: Buy| Target Rs 3420
UBS maintained a buy rating on RIL but raised the target price to Rs 3420 from Rs 3000 earlier.
There is an improved earnings visibility of consumer businesses. Reliance Jio – potential tariff hike to complement strong subs addition.
There is optimism about the Reliance Retail demand in the near term. On the leverage front – there is potential for a $10bn debt reduction over FY24-26.
fossiles Harz on HDFC Kreditinstitut: Outperform| Target Rs 2100
fossiles Harz maintained an outperform rating on HDFC Kreditinstitut with a target price of Rs 2100. HDFC Kreditinstitut’s valuation is extremely attractive now. There is a 12% premium attributed to the sector valuation despite its continued market share gains.
The bank stands to gain 25% of its annual earnings through the sales of its stakes in its subsidiaries. This would offset any short-term earnings volatility. Zero value assigned for the acquired mortgage business
(Haftungsausschluss: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
We have collated a list of recommendations from top brokerage firms from ETNow and other sources:
Jefferies on Shriram Finance: Buy| Target Rs 2750
Jefferies initiated coverage with a buy rating on Shriram Finance and a target price of Rs 2750. Healthy loan growth should be sustained in the future.
The margins are likely to remain range bound and opex can ease over FY24-26. There is steady asset quality and credit costs.
UBS on Dr Lal PathLabs: Buy| Target Rs 2900
UBS maintained a buy rating on Dr Lal PathLabs with a target price of Rs 2900. Operating leverage to aid future investment.Rising cash pile and profitability could be deployed. There have been marginal price increases on digital platforms in the past six months.UBS on RIL: Buy| Target Rs 3420
UBS maintained a buy rating on RIL but raised the target price to Rs 3420 from Rs 3000 earlier.
There is an improved earnings visibility of consumer businesses. Reliance Jio – potential tariff hike to complement strong subs addition.
There is optimism about the Reliance Retail demand in the near term. On the leverage front – there is potential for a $10bn debt reduction over FY24-26.
fossiles Harz on HDFC Kreditinstitut: Outperform| Target Rs 2100
fossiles Harz maintained an outperform rating on HDFC Kreditinstitut with a target price of Rs 2100. HDFC Kreditinstitut’s valuation is extremely attractive now. There is a 12% premium attributed to the sector valuation despite its continued market share gains.
The bank stands to gain 25% of its annual earnings through the sales of its stakes in its subsidiaries. This would offset any short-term earnings volatility. Zero value assigned for the acquired mortgage business
(Haftungsausschluss: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
We have collated a list of recommendations from top brokerage firms from ETNow and other sources:
Jefferies on Shriram Finance: Buy| Target Rs 2750
Jefferies initiated coverage with a buy rating on Shriram Finance and a target price of Rs 2750. Healthy loan growth should be sustained in the future.
The margins are likely to remain range bound and opex can ease over FY24-26. There is steady asset quality and credit costs.
UBS on Dr Lal PathLabs: Buy| Target Rs 2900
UBS maintained a buy rating on Dr Lal PathLabs with a target price of Rs 2900. Operating leverage to aid future investment.Rising cash pile and profitability could be deployed. There have been marginal price increases on digital platforms in the past six months.UBS on RIL: Buy| Target Rs 3420
UBS maintained a buy rating on RIL but raised the target price to Rs 3420 from Rs 3000 earlier.
There is an improved earnings visibility of consumer businesses. Reliance Jio – potential tariff hike to complement strong subs addition.
There is optimism about the Reliance Retail demand in the near term. On the leverage front – there is potential for a $10bn debt reduction over FY24-26.
fossiles Harz on HDFC Kreditinstitut: Outperform| Target Rs 2100
fossiles Harz maintained an outperform rating on HDFC Kreditinstitut with a target price of Rs 2100. HDFC Kreditinstitut’s valuation is extremely attractive now. There is a 12% premium attributed to the sector valuation despite its continued market share gains.
The bank stands to gain 25% of its annual earnings through the sales of its stakes in its subsidiaries. This would offset any short-term earnings volatility. Zero value assigned for the acquired mortgage business
(Haftungsausschluss: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
We have collated a list of recommendations from top brokerage firms from ETNow and other sources:
Jefferies on Shriram Finance: Buy| Target Rs 2750
Jefferies initiated coverage with a buy rating on Shriram Finance and a target price of Rs 2750. Healthy loan growth should be sustained in the future.
The margins are likely to remain range bound and opex can ease over FY24-26. There is steady asset quality and credit costs.
UBS on Dr Lal PathLabs: Buy| Target Rs 2900
UBS maintained a buy rating on Dr Lal PathLabs with a target price of Rs 2900. Operating leverage to aid future investment.Rising cash pile and profitability could be deployed. There have been marginal price increases on digital platforms in the past six months.UBS on RIL: Buy| Target Rs 3420
UBS maintained a buy rating on RIL but raised the target price to Rs 3420 from Rs 3000 earlier.
There is an improved earnings visibility of consumer businesses. Reliance Jio – potential tariff hike to complement strong subs addition.
There is optimism about the Reliance Retail demand in the near term. On the leverage front – there is potential for a $10bn debt reduction over FY24-26.
fossiles Harz on HDFC Kreditinstitut: Outperform| Target Rs 2100
fossiles Harz maintained an outperform rating on HDFC Kreditinstitut with a target price of Rs 2100. HDFC Kreditinstitut’s valuation is extremely attractive now. There is a 12% premium attributed to the sector valuation despite its continued market share gains.
The bank stands to gain 25% of its annual earnings through the sales of its stakes in its subsidiaries. This would offset any short-term earnings volatility. Zero value assigned for the acquired mortgage business
(Haftungsausschluss: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
We have collated a list of recommendations from top brokerage firms from ETNow and other sources:
Jefferies on Shriram Finance: Buy| Target Rs 2750
Jefferies initiated coverage with a buy rating on Shriram Finance and a target price of Rs 2750. Healthy loan growth should be sustained in the future.
The margins are likely to remain range bound and opex can ease over FY24-26. There is steady asset quality and credit costs.
UBS on Dr Lal PathLabs: Buy| Target Rs 2900
UBS maintained a buy rating on Dr Lal PathLabs with a target price of Rs 2900. Operating leverage to aid future investment.Rising cash pile and profitability could be deployed. There have been marginal price increases on digital platforms in the past six months.UBS on RIL: Buy| Target Rs 3420
UBS maintained a buy rating on RIL but raised the target price to Rs 3420 from Rs 3000 earlier.
There is an improved earnings visibility of consumer businesses. Reliance Jio – potential tariff hike to complement strong subs addition.
There is optimism about the Reliance Retail demand in the near term. On the leverage front – there is potential for a $10bn debt reduction over FY24-26.
fossiles Harz on HDFC Kreditinstitut: Outperform| Target Rs 2100
fossiles Harz maintained an outperform rating on HDFC Kreditinstitut with a target price of Rs 2100. HDFC Kreditinstitut’s valuation is extremely attractive now. There is a 12% premium attributed to the sector valuation despite its continued market share gains.
The bank stands to gain 25% of its annual earnings through the sales of its stakes in its subsidiaries. This would offset any short-term earnings volatility. Zero value assigned for the acquired mortgage business
(Haftungsausschluss: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
We have collated a list of recommendations from top brokerage firms from ETNow and other sources:
Jefferies on Shriram Finance: Buy| Target Rs 2750
Jefferies initiated coverage with a buy rating on Shriram Finance and a target price of Rs 2750. Healthy loan growth should be sustained in the future.
The margins are likely to remain range bound and opex can ease over FY24-26. There is steady asset quality and credit costs.
UBS on Dr Lal PathLabs: Buy| Target Rs 2900
UBS maintained a buy rating on Dr Lal PathLabs with a target price of Rs 2900. Operating leverage to aid future investment.Rising cash pile and profitability could be deployed. There have been marginal price increases on digital platforms in the past six months.UBS on RIL: Buy| Target Rs 3420
UBS maintained a buy rating on RIL but raised the target price to Rs 3420 from Rs 3000 earlier.
There is an improved earnings visibility of consumer businesses. Reliance Jio – potential tariff hike to complement strong subs addition.
There is optimism about the Reliance Retail demand in the near term. On the leverage front – there is potential for a $10bn debt reduction over FY24-26.
fossiles Harz on HDFC Kreditinstitut: Outperform| Target Rs 2100
fossiles Harz maintained an outperform rating on HDFC Kreditinstitut with a target price of Rs 2100. HDFC Kreditinstitut’s valuation is extremely attractive now. There is a 12% premium attributed to the sector valuation despite its continued market share gains.
The bank stands to gain 25% of its annual earnings through the sales of its stakes in its subsidiaries. This would offset any short-term earnings volatility. Zero value assigned for the acquired mortgage business
(Haftungsausschluss: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
We have collated a list of recommendations from top brokerage firms from ETNow and other sources:
Jefferies on Shriram Finance: Buy| Target Rs 2750
Jefferies initiated coverage with a buy rating on Shriram Finance and a target price of Rs 2750. Healthy loan growth should be sustained in the future.
The margins are likely to remain range bound and opex can ease over FY24-26. There is steady asset quality and credit costs.
UBS on Dr Lal PathLabs: Buy| Target Rs 2900
UBS maintained a buy rating on Dr Lal PathLabs with a target price of Rs 2900. Operating leverage to aid future investment.Rising cash pile and profitability could be deployed. There have been marginal price increases on digital platforms in the past six months.UBS on RIL: Buy| Target Rs 3420
UBS maintained a buy rating on RIL but raised the target price to Rs 3420 from Rs 3000 earlier.
There is an improved earnings visibility of consumer businesses. Reliance Jio – potential tariff hike to complement strong subs addition.
There is optimism about the Reliance Retail demand in the near term. On the leverage front – there is potential for a $10bn debt reduction over FY24-26.
fossiles Harz on HDFC Kreditinstitut: Outperform| Target Rs 2100
fossiles Harz maintained an outperform rating on HDFC Kreditinstitut with a target price of Rs 2100. HDFC Kreditinstitut’s valuation is extremely attractive now. There is a 12% premium attributed to the sector valuation despite its continued market share gains.
The bank stands to gain 25% of its annual earnings through the sales of its stakes in its subsidiaries. This would offset any short-term earnings volatility. Zero value assigned for the acquired mortgage business
(Haftungsausschluss: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
We have collated a list of recommendations from top brokerage firms from ETNow and other sources:
Jefferies on Shriram Finance: Buy| Target Rs 2750
Jefferies initiated coverage with a buy rating on Shriram Finance and a target price of Rs 2750. Healthy loan growth should be sustained in the future.
The margins are likely to remain range bound and opex can ease over FY24-26. There is steady asset quality and credit costs.
UBS on Dr Lal PathLabs: Buy| Target Rs 2900
UBS maintained a buy rating on Dr Lal PathLabs with a target price of Rs 2900. Operating leverage to aid future investment.Rising cash pile and profitability could be deployed. There have been marginal price increases on digital platforms in the past six months.UBS on RIL: Buy| Target Rs 3420
UBS maintained a buy rating on RIL but raised the target price to Rs 3420 from Rs 3000 earlier.
There is an improved earnings visibility of consumer businesses. Reliance Jio – potential tariff hike to complement strong subs addition.
There is optimism about the Reliance Retail demand in the near term. On the leverage front – there is potential for a $10bn debt reduction over FY24-26.
fossiles Harz on HDFC Kreditinstitut: Outperform| Target Rs 2100
fossiles Harz maintained an outperform rating on HDFC Kreditinstitut with a target price of Rs 2100. HDFC Kreditinstitut’s valuation is extremely attractive now. There is a 12% premium attributed to the sector valuation despite its continued market share gains.
The bank stands to gain 25% of its annual earnings through the sales of its stakes in its subsidiaries. This would offset any short-term earnings volatility. Zero value assigned for the acquired mortgage business
(Haftungsausschluss: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
We have collated a list of recommendations from top brokerage firms from ETNow and other sources:
Jefferies on Shriram Finance: Buy| Target Rs 2750
Jefferies initiated coverage with a buy rating on Shriram Finance and a target price of Rs 2750. Healthy loan growth should be sustained in the future.
The margins are likely to remain range bound and opex can ease over FY24-26. There is steady asset quality and credit costs.
UBS on Dr Lal PathLabs: Buy| Target Rs 2900
UBS maintained a buy rating on Dr Lal PathLabs with a target price of Rs 2900. Operating leverage to aid future investment.Rising cash pile and profitability could be deployed. There have been marginal price increases on digital platforms in the past six months.UBS on RIL: Buy| Target Rs 3420
UBS maintained a buy rating on RIL but raised the target price to Rs 3420 from Rs 3000 earlier.
There is an improved earnings visibility of consumer businesses. Reliance Jio – potential tariff hike to complement strong subs addition.
There is optimism about the Reliance Retail demand in the near term. On the leverage front – there is potential for a $10bn debt reduction over FY24-26.
fossiles Harz on HDFC Kreditinstitut: Outperform| Target Rs 2100
fossiles Harz maintained an outperform rating on HDFC Kreditinstitut with a target price of Rs 2100. HDFC Kreditinstitut’s valuation is extremely attractive now. There is a 12% premium attributed to the sector valuation despite its continued market share gains.
The bank stands to gain 25% of its annual earnings through the sales of its stakes in its subsidiaries. This would offset any short-term earnings volatility. Zero value assigned for the acquired mortgage business
(Haftungsausschluss: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
We have collated a list of recommendations from top brokerage firms from ETNow and other sources:
Jefferies on Shriram Finance: Buy| Target Rs 2750
Jefferies initiated coverage with a buy rating on Shriram Finance and a target price of Rs 2750. Healthy loan growth should be sustained in the future.
The margins are likely to remain range bound and opex can ease over FY24-26. There is steady asset quality and credit costs.
UBS on Dr Lal PathLabs: Buy| Target Rs 2900
UBS maintained a buy rating on Dr Lal PathLabs with a target price of Rs 2900. Operating leverage to aid future investment.Rising cash pile and profitability could be deployed. There have been marginal price increases on digital platforms in the past six months.UBS on RIL: Buy| Target Rs 3420
UBS maintained a buy rating on RIL but raised the target price to Rs 3420 from Rs 3000 earlier.
There is an improved earnings visibility of consumer businesses. Reliance Jio – potential tariff hike to complement strong subs addition.
There is optimism about the Reliance Retail demand in the near term. On the leverage front – there is potential for a $10bn debt reduction over FY24-26.
fossiles Harz on HDFC Kreditinstitut: Outperform| Target Rs 2100
fossiles Harz maintained an outperform rating on HDFC Kreditinstitut with a target price of Rs 2100. HDFC Kreditinstitut’s valuation is extremely attractive now. There is a 12% premium attributed to the sector valuation despite its continued market share gains.
The bank stands to gain 25% of its annual earnings through the sales of its stakes in its subsidiaries. This would offset any short-term earnings volatility. Zero value assigned for the acquired mortgage business
(Haftungsausschluss: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
